Applied DNA Sciences partners with GenXys Health Care Systems

Applied DNA Sciences announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, will utilize the GenXys Health Care Systems suite of clinical decision support software for interpretation and reporting of ADCL’s New York State Department of Health-approved TR8 pharmacogenomic test. The partnership is designed to improve patient outcomes and reduce healthcare costs through a data-driven approach that relates an individual’s genetic factors to potential responses to prescription drugs. Applied DNA’s TR8 PGx assay simultaneously interrogates 120 genetic variants across more than 30 genes that have been shown to affect the rate with which the body absorbs, activates, distributes, and metabolizes drugs, which can, in turn, impact the efficacy and safety of medications. The genetic variations targeted by TR8 PGx are relevant to a broad range of medicines, including cardiac, pain management, cancer, and psychiatric drugs.